Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRINOX in Borderline Resectable or Locally Advanced Pancreatic Cancer
NCT01359007Phase 2Terminated
- Sponsor
- University of Oklahoma
- Start
- May 2011
- Primary completion
- Oct 2013
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, oxaliplatin, folinic acid, fluorouracil in pancreatic ductal adenocarcinoma (PDAC), sponsored by University of Oklahoma. Started May 2011; status: terminated.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumaboxaliplatinfolinic acidfluorouracil
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01359007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01359007.